What procalcitonin brings to management of sepsis in the ICU
- PMID: 21138601
- PMCID: PMC3220031
- DOI: 10.1186/cc9330
What procalcitonin brings to management of sepsis in the ICU
Abstract
In inflammatory states, particularly in response to infectious stimuli, local procalcitonin (PCT) production rises, and because these tissues cannot further process PCT into calcitonin, serum levels increase. In the critical care setting, PCT should be considered a useful tool to help physicians in some specific, although frequent, situations. Serial measurements of PCT levels may indicate the effectiveness of medical decisions such as the appropriateness of antibiotic therapy, the detection of new infections, and the exclusion of a diagnosis of sepsis. PCT-guided algorithms may also help to decrease the duration of antimicrobial therapy. However, the role of PCT as a prognostic marker in critically ill patients is controversial. In a study by Karlsson and colleagues, PCT concentrations did not differ between hospital survivors and nonsurvivors, but the outcome was better in patients whose PCT concentrations decreased more than 50%. The study of PCT kinetics thus could offer an individual risk assessment in patients with severe sepsis.
Comment in
-
In critically ill patients the procalcitonin level can be misleading.Crit Care. 2011;15(2):422. doi: 10.1186/cc10132. Epub 2011 Apr 28. Crit Care. 2011. PMID: 21542896 Free PMC article. No abstract available.
Comment on
-
Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study.Crit Care. 2010;14(6):R205. doi: 10.1186/cc9327. Epub 2010 Nov 15. Crit Care. 2010. PMID: 21078153 Free PMC article.
References
-
- Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T, the CAPNETZ study group. Cardiovascular and inflammatory biomarkers to predict short-and long-term survival in community-acquired pneumonia. Am J Respir Crit Care Med. 2010. in press . - PubMed
-
- Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M. Prorata trial group. Use of procalcitonin to reduce patient's exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375:463–474. doi: 10.1016/S0140-6736(09)61879-1. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical